Overexpression of NCAPH is upregulated and predicts a poor prognosis in prostate cancer

Abstract

Prostate cancer (PCa) is one of the most frequently diagnosed types of cancer worldwide. However, there remains a lack of accurate biomarkers to predict the outcome of PCa. Non-SMC condensin I complex subunit H (NCAPH) encodes a regulatory subunit of the non-structural maintenance of chromosomes condensin I complex. The present study aimed to investigate whether NCAPH may be a novel diagnostic marker for PCa by analyzing public datasets, including GSE17951, GSE55945 and a dataset from The Cancer Genome Atlas. The current results, to the best of our knowledge, demonstrated for the first time that NCAPH is significantly upregulated in PCa. Furthermore, it was identified that NCAPH expression is higher in stage T3/T4 and N1 PCa samples compared with stage T2 and N0 PCa samples, respectively. Kaplan-Meier analysis demonstrated that overexpression of NCAPH is associated with poor survival of patients with PCa. Bioinformatics analysis revealed that NCAPH is involved in regulating the PCa cell cycle by interacting with a number of proteins, including non-SMC condensin I complex subunit D2, non-SMC condensin I complex subunit G, structural maintenance of chromosomes 4, structural maintenance of chromosomes 2, Aurora kinase A, Aurora kinase B, cyclin-dependent kinase 1, H2A histone family member Z, POC1 centriolar protein A and histone cluster 2 H2A family member C. In summary, the present results suggest NCAPH may be a novel and beneficial diagnostic and therapeutic target in PCa.

Non‐SMC condensin I complex subunit H enhances proliferation, migration, and invasion of hepatocellular carcinoma

“…NCAPH encodes a regulatory subunit in the non‐SMC condensing I complex and is required for the conversion of interphase chromatin into condensed chromosomes . Previous studies have revealed that abnormal expression of NCAPH is associated with colon cancer and prostate cancer . However, there have been no relevant reports about the clinical relevance and functional role of NCAPH in HCC.…”

“…9 Previous studies have revealed that abnormal expression of NCAPH is associated with colon cancer and prostate cancer. 10,11 However, there have been no relevant reports about the clinical relevance and functional role of NCAPH in HCC. In this study, we aimed to explore NCAPH expression in HCC tissues and investigate the functions of NCAPH in HCC cells.…”

The Yin and Yang of Autosomal Recessive Primary Microcephaly Genes: Insights from Neurogenesis and Carcinogenesis

“…In PCa, MCPH23 interacts with a variety of proteins during the regulation of PCa-associated cell cycles. These proteins include Aurora kinase A, Aurora kinase B, and cyclin-dependent kinase 1 [38]. Consistently, the deletion of low-density lipoprotein-related receptor 5 inhibits liver cancer cell proliferation via destabilizing MCPH24 in a β-catenin-independent way [111].…”

“…The knockdown or inhibited expression of these genes may be a potential therapeutic method for cancer treatment [31][32][33]. In addition, the overexpression of MCPH2, MCPH5, MCPH7, MCPH14, MCPH20, MCPH21, MCPH23, and MCPH24 is associated with aggressiveness and poor outcome in patients with cancer [28,[34][35][36][37][38][39]. However, MCPH1 and MCPH15 are downregulated in tumor tissues or cancer cell lines and are considered as novel tumor suppressor genes [40,41].…”

Membrane Protein Metabolism in UNG-Activated NCAPH and RFC4 Subnetworks for Viral HCC|blood Cancer Development Via Inside-Out Microtubule Binding

“…NCAPH is upregulated in endometrial cancer and associated with poor clinicopathologic characteristics [5]. Overexpression of NCAPH is upregulated and predicts a poor prognosis in prostate cancer [6]. However, NCAPH and RFC4 subnetworks containing CDKN3 (feedback) has not been explored for the novel molecular and cellular mechanisms of HCC (HBV or HCV) related cancer development from high UNG-activated upstream network.…”